Skip to content
Treatments · also called picosecond laser, 피코레이저, PicoSure

Pico laser for pigmentation: what the pooled trials actually found

Picosecond lasers are sold as the newer, better option for pigmentation. For melasma, a 2026 meta-analysis of 52 trials found they did not beat controls.

Author
Aesthetics Korea Editorial Team
Medical review
Reviewed by 2 doctorsSee methodology
Published
8 September 2026
Last updated
8 September 2026
Last reviewed
5 min read

Short answer

Does pico laser work better than older lasers for pigmentation?

A picosecond laser delivers pulses so short that pigment is shattered largely by pressure rather than heat, which in principle spares surrounding tissue. For melasma specifically, that principle has not translated into better pooled results: a 2026 meta-analysis of 52 randomised trials found picosecond lasers did not significantly outperform controls, while older low-fluence Q-switched Nd:YAG lasers did. Pigmentation is not one condition, and this finding is about melasma.

Key facts

Technology
Laser pulses in the picosecond range, shattering pigment mainly by photoacoustic effect rather than heat
Purpose
Pigmented lesions and tattoo removal; widely marketed for melasma and general "toning"
Pain
Brief snapping sensation per pulse; topical anaesthetic is common
Downtime
Transient redness and a localised burning sensation are common
Sessions
Sold as a course; melasma in particular is managed rather than cured
Results timeline
Gradual over a course, and prone to recurrence in melasma

What a picosecond laser is

Laser treatment of pigment works by depositing energy into pigment faster than the surrounding tissue can carry the heat away. The shorter the pulse, the more the effect is confined to the target.

A picosecond laser fires in pulses measured in trillionths of a second — around a thousand times shorter than the nanosecond Q-switched lasers that preceded it. At that speed the dominant mechanism shifts from heating to a photoacoustic one: pigment is shattered by pressure rather than cooked, which in principle means less collateral heat in the surrounding skin.

That is a genuinely good principle, and it is the entire basis of how these devices are sold.

What the pooled trials found for melasma

A 2026 systematic review and meta-analysis in Cureus pooled 52 randomised controlled trials covering 1,058 participants. For melasma, the headline result is not the one the marketing predicts:

  • Picosecond lasers did not significantly outperform controls — mean difference −0.11 (95% CI −0.79 to 0.57).
  • Low-fluence Q-switched Nd:YAG at 1064 nm did — mean difference 1.47 (95% CI 0.08 to 2.85).
  • Across all laser types pooled together, the trend was not statistically significant (MD 0.70; p = 0.2682).

So in the pooled randomised evidence for melasma, the older and cheaper technology outperformed the newer and more expensive one. The reviewers note that optimal picosecond parameters for different wavelengths are still being refined — this is a "not yet demonstrated" rather than a "disproven" — but the practical point for a patient stands: paying a premium for pico as a melasma treatment is not currently supported by the pooled trials.

Being precise about what this does and does not say

Two cautions, because it would be easy to over-read this.

It is about melasma. Pigmentation is not one condition. Melasma is a specific, chronic, hormonally and sun-influenced pattern that recurs, and it is the hardest pigment problem there is. Picosecond platforms have other uses, tattoo removal among them, that this analysis does not address.

It is about the pooled average. Individual trials and individual patients vary, and device settings differ enormously. What the meta-analysis rules out is a reliable across-the-board advantage, not the possibility of benefit in a particular case.

The reviewers' own conclusion keeps that balance: lasers, "particularly low-fluence QSNY lasers, are effective adjunctive tools for melasma management. However, they should not be considered a panacea. Optimal clinical management requires a multi-modal approach." Adjunctive. Multi-modal. Not a cure.

The risk that matters in pigmented skin

The review reports no serious adverse events, with transient redness and localised burning common. The complication to understand is pigmentary: post-inflammatory hyperpigmentation and hypopigmentation, occurring particularly at high fluences.

That is the whole reason "low-fluence" appears in the finding that did work. Treating pigment too aggressively can provoke more pigment — the opposite of what you came for — and the risk is greater in darker skin. Asking what fluence is being used, and why that choice for your skin type, is a reasonable and revealing question.

Laser toning, and the naming problem

Korean clinics sell "laser toning", "dual toning", "pico toning" and similar. These are techniques — repeated low-fluence passes across an area — not devices, and the same name may be delivered on a Q-switched or a picosecond platform depending on the clinic.

Since the pooled evidence distinguishes by device and fluence rather than by marketing name, the question that gets you real information is: which device, which wavelength, what fluence, how many passes.

Questions to ask a Korean clinic

  • Which device and wavelength, and what is its Korean product name?
  • What fluence, and why that setting for my skin type?
  • Is this melasma, or another kind of pigmentation? They are not managed the same way.
  • What is the plan if my pigmentation darkens after a session?
  • What happens if I stop — and what does maintenance look like?

The bottom line

Picosecond lasers shatter pigment with very short pulses, which is sound in principle. For melasma, a 2026 meta-analysis of 52 randomised trials found they did not significantly outperform controls while older low-fluence Q-switched Nd:YAG lasers did. Melasma is managed rather than cured, high fluences can make pigmentation worse, and the newest platform in the room is not automatically the right one.

Frequently asked questions

Is pico laser better than the older Q-switched lasers?
For melasma, the pooled evidence says no. The 2026 meta-analysis of 52 randomised trials found picosecond lasers did not significantly outperform controls (MD −0.11; 95% CI −0.79 to 0.57), while low-fluence Q-switched Nd:YAG did show a significant improvement (MD 1.47; 95% CI 0.08 to 2.85). Newer and more expensive is not the same as more effective.
So pico lasers do not work?
That is not what the finding says. It is specific to melasma, which is a notoriously difficult and recurrent condition. Picosecond technology has other established uses, and the reviewers note its optimal parameters for different wavelengths are still being refined. What the evidence does not support is paying a premium for it as a melasma treatment on the assumption that newer means better.
What is melasma, and why is it different?
It is a chronic, patterned facial pigmentation strongly influenced by sun and hormones. It recurs. That is why the reviewers describe lasers as adjunctive tools rather than a cure, and why any clinic promising to clear it in a set number of sessions is overpromising.
Can laser make pigmentation worse?
Yes, and this is the risk to understand. The review reports post-inflammatory hyperpigmentation and hypopigmentation occurring particularly with high fluences. In darker skin this is the central concern, and it is a reason to ask what settings are being used and why.
What is laser toning then?
Toning is a technique — repeated low-fluence passes over an area — rather than a device, and it is most often done with a Q-switched Nd:YAG. Confusingly, it is also sold on picosecond platforms. Ask which device and which setting, not which marketing name.
What should I ask a Korean clinic?
Which device and wavelength, at what fluence, and why that choice for your skin type. What the plan is if pigmentation darkens after treatment. And what happens to the result if you stop — because for melasma, maintenance is the normal case.

Medical evidence

  1. Systematic review2026n = 1058
    Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

    "Laser-based therapies, particularly low-fluence QSNY lasers, are effective adjunctive tools for melasma management. However, they should not be considered a panacea. Optimal clinical management requires a multi-modal approach..."

Sources

Listed in the order they are used. Source class follows the methodology.

  1. 1.Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis, Cureus, 2026Peer-reviewed researchaccessed 2026-09-0852 randomised controlled trials, 1,058 participants. Picosecond lasers did not significantly outperform controls (MD −0.11; 95% CI −0.79 to 0.57); low-fluence Q-switched Nd:YAG 1064 nm did (MD 1.47; 95% CI 0.08 to 2.85). Overall pooled analysis showed a non-significant trend (MD 0.70; p = 0.2682). No serious adverse events; transient erythema and localised burning common; post-inflammatory hyper- and hypopigmentation particularly with high fluences.
  2. 2.의료기기 안심책방 (MFDS medical device information portal), Ministry of Food and Drug SafetyGovernment / public bodyaccessed 2026-09-08Where the Korean licence for a specific laser platform is looked up, under its Korean product name.
  3. 3.대한피부과의사회 — 피부과 전문의 구별법, Korean Academy of DermatologyProfessional bodyaccessed 2026-09-08Cited for what board certification requires. Fluence selection in pigmented skin is where laser treatment most often goes wrong, so who chooses the settings matters.